北海康成-B(01228.HK)附屬擬委任百洋附屬公司爲獨家合同銷售組織(CSO)以推廣集團若幹產品
格隆匯8月12日丨北海康成-B(01228.HK)公告,於2025年8月11日,集團的兩家附屬公司與青島百洋醫藥股份有限公司(於深圳證券交易所上市的公司,股票代碼:301015)("百洋醫藥")的一家附屬公司("百洋附屬公司")正式建立戰略合作關係。
上述各方已訂立一份戰略合作及獨家商業服務協議,據此,相關附屬公司已同意委任百洋附屬公司爲獨家合同銷售組織(CSO),於中國內地、香港及澳門推廣集團的若幹產品,惟須受集團相關成員公司與該等產品各自的授權方所訂立的上遊授權協議(包括(在適用情況下)相關授權方的同意)所規限。商業服務協議亦訂明,百洋附屬公司的聯屬公司可按百洋的選擇擔任該等產品於相關地區的分銷商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.